Clinical Trial Update: Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia [Phase 3]

View source ↗

Summary

An open-label extension study of aripiprazole intramuscular depot (OPC-14597, Lu AF41155) in patients with schizophrenia completed Phase 3 testing. Results were…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Aripiprazole intramuscular depot (OPC-14597 / Lu AF41155) (aripiprazole)

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED | Results posted: 2015-03-31